Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05112549 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

Study acronym: IT-PD1
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 30, 2025 to Dec 31, 2026
    • Study completion date: Sep 30, 2026 to Sep 30, 2027
    v7
  2. Study sites: 7 to 9
    • Eligibility criteria expanded, about 62 words
    v6
  3. Re-verified, no change to tracked fieldsv5
  4. Primary completion date: Sep 30, 2023 to Sep 30, 2025
    • Study sites: 5 to 7
    • Study completion date: Sep 30, 2024 to Sep 30, 2026
    • Eligibility criteria expanded, about 16 words
    v4
  5. Study sites: 1 to 5
    • Interventions: Nivolumab 10 MG/ML [Opdivo] (Drug) to Nivolumab [Opdivo] (Drug)
    • Study title expanded, about 3 words
    v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To determine the safety of intrathecal (IT) PD1 antibody for Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease of solid tumors.
Trial Details
NCT Number NCT05112549
Lead Sponsor University Hospital Tuebingen
Conditions
(from sponsor)		 Leptomeningeal Disease
Related terms Meningeal Neoplasms
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov